Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
NCT Number: NCT06164873
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Phase 3
Beijing, Beijing Municipality, 100010, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For subjects with T2D at screening:
Exclusion criteria
For subjects without T2D at screening:
For subjects with T2D at screening:
Once-weekly injections of gradually increased doses of IBI362
Once-weekly injections of volume-matched placebo
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Time frame: Week 60
Innovent Biologics (Suzhou) Co. Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04335799
Body Weight, Nutrition Disorders
Tampa, Florida, United States
View Trial DetailsNCT05198765
Body Weight, Diabetes Mellitus
Minneapolis, Minnesota, United States
View Trial DetailsNCT00739362
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT07400653
Body Weight, Diabetes Mellitus
Anaheim, California, United States
View Trial Details